Key Takeaways BMY's Sotyktu met primary and multiple secondary endpoints in a phase III PsA study. Sotyktu showed superior efficacy over placebo at Week 16 and sustained responses through Week 52. RayzeBio inked a $1.35B licensing deal for Philochem's prostate cancer therapy, OncoACP3.Bristol Myers (BMY) announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint.Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor w ...

会议背景 - 高盛第46届全球医疗健康会议第三天，Bristol-Myers Squibb公司高管参与讨论，包括CEO Christopher S Boerner和首席商务官Adam Lenkowsky [1] - 会议主持人为高盛美国制药行业分析师Asad Haider [1] 行业环境 - 制药行业面临政策相关不确定性，公司与政府对话方向积极但仍处早期阶段 [4] - 重点关注MFN（Most Favored Nation）政策可能对行业产生的影响 [5] 公司动态 - Bristol-Myers Squibb高管表示正积极与政府进行沟通 [5]

Bristol-Myers Squibb Company (BMY) FY Conference June 11, 2025 10:00 AM ET Speaker0 All right. We're just right about at time. So let's get started. Welcome to day three of our Healthcare Conference. My name is Assad Haidar. I'm The U. S. Pharmaceutical Analyst here at Goldman Sachs. I'm very, very pleased and privileged to have the Bristol Myers team over here, Chris Boerner, Chairman and CEO and Adam Wenkowski, Chief Commercial Officer. Chris and Adam, welcome, and thank you for being with us. It's great ...

In the latest trading session, Bristol Myers Squibb (BMY) closed at $49, marking a +1.22% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.09%.The the stock of biopharmaceutical company has risen by 4.22% in the past month, leading the Medical sector's gain of 2.17% and undershooting the S&P 500's gain of 7.21%.Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company is predicted to post an ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. ...

Key Takeaways BMY will co-develop BioNTech's BNT327, targeting PD-L1 and VEGF-A in multiple solid tumor types The billion-dollar deal includes an upfront payment of $1.5 billion, along with other payments BMY seeks pipeline growth as drugs like Revlimid and Abraxane lose ground to genericsBristol Myers Squibb (BMY) recently announced a strategic collaboration agreement with BioNTech (BNTX) for the global co-development and co-commercialization of the latter’s investigational bispecific antibody BNT327 acr ...

The primary goal of the Cash Flow Kingdom Income Portfolio is to produce an overall yield in the 7% - 10% range. We accomplish this by combining several different income streams to form an attractive, steady portfolio payout. The portfolio's price can fluctuate, but the income stream remains consistent. Start your free two-week trial today!He is a contributing author for the investing group Cash Flow Club where along with Darren McCammon, they focus on company cash flows and their access to capital. Core fe ...

Bristol Myers (BMY) announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) across multiple solid tumor indications. The decision applies to all 27 EU member states, as well as Iceland, Norway and Liechtenstein.Nivolumab for subcutaneous (SC) use, co-formulated with recombinant human hyaluronidase (rHuPH20), is indicated across multiple previously approved adult solid tumors as monotherapy, monotherapy maintenance following completion of nivolumab plus Yer ...

Shares of Bristol Myers (BMY) have lost 20.7% in the past three months compared with the industry’s decline of 9.6%. The stock has also underperformed the sector and the S&P 500 during this period.While the year started on a positive note and BMY was faring well (outperforming the market), the stock has been on the downslide for the past couple of months.BMY Underperforms Industry, Sector & S&P 500 IndexImage Source: Zacks Investment ResearchEven though the first-quarter performance was better-than-expected ...

Bristol-Myers Squibb Company (NYSE:BMY) Bernstein 41st Annual Strategic Decisions Conference May 28, 2025 3:30 PM ET Company Participants Chris Boerner - Chief Executive Officer & Chairman Conference Call Participants Courtney Breen - Bernstein Courtney Breen Fantastic. Hi, everyone. It's great to have you here for this fireside, the first of our pharmaceutical fireside during the SDC. My name is Courtney Breen. I am the U.S. biopharma analyst here at Bernstein. And I am thrilled to have Chris Boerner here ...